Skip to main content

Product Value—GORE® VIABAHN® Endoprosthesis

Clinical and economic value in dialysis access

GORE VIABAHN Endoprosthesis

For end-stage renal disease (ESRD) patients who require regular hemodialysis, maintaining a functioning dialysis access circuit is essential.

In patients who use arteriovenous (AV) grafts for hemodialysis, the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface* can increase clinical value by improving patency1 and reducing the number of future interventions when compared to percutaneous transluminal angioplasty (PTA).2  

When treating one of the most common complication of AV grafts, the VIABAHN® Device demonstrated 40% fewer future interventions2 which resulted in an 18% reduction of total costs over 2 years compared to PTA ($30,329 versus $37,206; P = .027)2.

18% reduction of total costs versus PTA over 2 years:
$30,329 versus $37,206 per patient (P = .027)2 

Chart comparing benefits of VIABAHN device to treat the most common AV graft complication

Three people discussing documents

Connect with one of our Corporate Account Directors to learn more about the value Gore can deliver to your healthcare institution.

 

Contact us >

The Future of Value Analysis

A Handbook for Health Care Professionals

Read perspectives from value analysis professionals who share their thoughts regarding the importance of effective collaboration, paradigm shifts with determining value, and the critical focus on the future of healthcare.

 

Download the handbook >

* As used by Gore, Heparin Bioactive Surface refers to Gore’s proprietary CBAS Heparin Surface.

† AV graft thrombosis occurs when blood stops flowing through the AV graft, resulting in an inability to perform hemodialysis treatment.  In the Gore REVISE Clinical Study, graft thrombosis was the most common indication for patient enrollment.1

REFERENCES

  1. Vesely T, DaVanzo W, Behrend T, Dwyer A, Aruny J. Balloon angioplasty versus Viabahn stent graft for treatment of failing or thrombosed prosthetic hemodialysis grafts. Journal of Vascular Surgery 2016; 64(5):1400-1410.e1.http://www.sciencedirect.com/science/article/pii/S0741521416301756
  2. Mohr BA, Sheen AL, Roy-Chaudhury P, Schultz SR, Aruny JE; REVISE Investigators.  Clinical and economic benefits of stent grafts in dysfunctional and thrombosed hemodialysis access graft circuits in the REVISE Randomized Trial.  Journal of Vascular & Interventional Radiology 2019;30(2):203-211.e4.https://www.jvir.org/article/S1051-0443(18)31772-X/fulltext